Skip to main content

Bioprocess Technology Market Report 2028 | Size, Share, Growth, Trends, Revenue, Competitive Landscape, Forecast

Key Companies Covered in the Bioprocess Technology Market Research Report are UNIVERCELLS, Koninklijke Philips N.V., Abbott, BD, Thermo Fisher Scientific, F. Hoffmann-La Roche , Sartorius AG, Danaher

Pune, India, Sept. 07, 2021 (GLOBE NEWSWIRE) — The global bioprocess technology market size is expected to gain momentum owing to the rising incidence of infectious diseases during the forecast period. This information is published by Fortune Business Insights™ in an upcoming report, titled, “Bioprocess Technology Market 2021-2028.” Growth in the biotechnology sector, increased R&D expenditure, growing need for vaccine manufacturing, and technical improvements are key growth factors for this market. On the other hand, strict regulatory rules and the high price of equipment are limiting market expansion for bioprocess technology. Biopharmaceutical businesses will face significant challenges in increasing manufacturing capacity and shortening it’s time to bring medicines to market. Bioprocess equipment manufacturers would be expected to provide creative, safe, and high-efficiency solutions to satisfy the increased competition from biopharmaceutical firms.

Industry Development-

February 2019: UNIVERCELLS launched scale-x carbo, a bench-scale automated cell culture system for expressing and concentrating viral therapeutic substances suitable for R&D and clinical material production.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bioprocess-technology-market-103097


COVID-19 Impact-

Cumulative Impact of Covid-19 on Bioprocess Industry

The appearance of COVID-19 has brought the world to a halt. We recognize that the healthcare crisis has had an extraordinary impact on businesses across industries. Rising government and corporate funding may aid in the fight against this extremely infectious illness. Some industries are suffering, while others are flourishing. During this time of fast expansion, the sector has learned to be adaptable and agile. This flexibility is already assisting the industry in retooling for quick development and manufacturing of pandemic vaccines, treatments, equipment, and diagnostics, adapting to changes brought about by this global mobilization of resources.


To get to know more about the short-term and long-term impact of COVID19 on this market, please visit: https://www.fortunebusinessinsights.com/bioprocess-technology-market-103097


Segments-

By product, the market is segmented into instruments and consumable accessories. Instruments consist of bioprocess analyzers, gas analyzers, osmometers, cell counter system, bioreactors, and incubator. On the other hand, consumable accessories consist of cultural media and reagents. On the basis of end-users, the market is segregated into biotechnology and biopharmaceuticals companies, research & academic institutes, and others. Finally, by geography, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

What does the Report Offer?

The bioprocess technology research examines market variables impacting demand and supply, key dynamics affecting the market throughout the forecast period, such as drivers, constraints, opportunities, and future trends. The study also includes a comprehensive PEST analysis for each of the five regions.

Drivers & Restraints-

Growing Demand for Protein to Stimulate Growth

The global bioprocess technology market growth is expected to grow due to the rising demand for protein during the projected period. The need for recombinant proteins for medicinal purposes is increasing. Human proteins derived from genetic engineering play an important role in the therapeutic pharmaceuticals industry. Recombinant therapeutic proteins are significant treatments for a wide range of illnesses, including diabetic, cancers, contagious diseases, hepatitis, and iron deficiency. Antibodies, FC fusion proteins, hormonal, interleukin, enzymes, and anticoagulants are examples of common therapeutic proteins. As the prevalence of chronic illnesses such as diabetes and cancer rises, the segment will grow. Furthermore, recombinant proteins can be used to study fusion proteins.


Get your Customized Research Report:

https://www.fortunebusinessinsights.com/enquiry/customization/bioprocess-technology-market-103097


REGIONAL INSIGHTS

Growing R&D Activities to Promote Growth in North America

North America is expected to hold the largest global bioprocess technology market share during the forecast period. The existence of large-scale pharmaceutical and biotechnology facilities in the United States, together with increasing biopharmaceutical R&D, has significantly contributed to the region’s supremacy. Furthermore, the North American area is home to a large number of contractual manufacturing firms that are integrating disposables into their operations.

Asia Pacific is expected to have a sizable share of the market. This market’s expansion is fuelled by overall biopharmaceutical industry growth, expenditures by major market participants in Asia nations, increased government support, advancements in R&D infrastructure, and rising knowledge and academic excellence.

Competitive Landscape-

Increasing Number of Mergers to Create Opportunities for Market Growth

The research provides a thorough analysis of the following prominent companies in bioprocess technology, including their competitive landscape, capacity, and most recent events such as mergers, acquisitions, and investment, storage expansions, and facility turnarounds.

List of Key Players Profiled in the Global Market for Bioprocess Technology:

  • UNIVERCELLS
  • Koninklijke Philips N.V.
  • Abbott
  • BD
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche
  • Sartorius AG
  • Danaher


Enquire before buying:

https://www.fortunebusinessinsights.com/enquiry/queries/bioprocess-technology-market-103097


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights™

LinkedIn | Twitter | Blogs

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.